Sign in
T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
Journal article   Open access  Peer reviewed

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma

Alison J. Moskowitz, Gunjan Shah, Heiko Schöder, Nivetha Ganesan, Helen Hancock, Theresa Davey, Leslie Perez, Samia Sohail, Alayna Santarosa, Charisse Capadona, …
HemaSphere, Vol.6(Suppl), pp.45-46
2022-10-03

Abstract

Refractory Relapsed
url
https://doi.org/10.1097/01.HS9.0000890964.54059.2cView
Published (Version of record) Open

Metrics

25 Record Views

Details